Liminatus Pharma (NASDAQ:LIMN) Stock Price Down 3.2% – Should You Sell?

Liminatus Pharma Inc. (NASDAQ:LIMN)’s stock price fell 3.2% during trading on Thursday . The company traded as low as $0.5819 and last traded at $0.5903. 96,659 shares were traded during mid-day trading, a decline of 18% from the average session volume of 117,268 shares. The stock had previously closed at $0.61.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Wall Street Zen downgraded Liminatus Pharma from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 22nd. Weiss Ratings restated a “sell (e+)” rating on shares of Liminatus Pharma in a research note on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

Liminatus Pharma Price Performance

The firm has a market cap of $15.98 million and a PE ratio of -4.92. The business has a 50-day moving average price of $0.78 and a two-hundred day moving average price of $2.13.

Liminatus Pharma (NASDAQ:LIMN) last issued its quarterly earnings data on Friday, November 14th. The company reported ($0.07) EPS for the quarter.

Liminatus Pharma Company Profile

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.